Iovance Biotherapeutics Inc
IOVA2.060USD
0.0000.00%
收盘 10/31, 16:00（美东）报价延迟15分钟
704.35M总市值
亏损市盈率 TTM
关于 Iovance Biotherapeutics Inc 公司
Iovance Biotherapeutics, Inc. 是一家临床阶段的生物制药公司。该公司开发并提供针对实体瘤癌症患者的肿瘤浸润淋巴细胞 (TIL) 疗法。其主要候选产品 Amtagvi (lifileucel) 是一种肿瘤衍生的自体 T 细胞免疫疗法，用于治疗之前用 PD-1 阻断抗体治疗的不可切除或转移性黑色素瘤成年患者，如果 BRAF V600 突变阳性，则使用 BRAF 抑制剂（含或不含 MEK 抑制剂）。该公司还销售用于 Amtagvi 治疗方案的 Proleukin (aldesleukin)，一种白细胞介素-2 或 IL-2 产品。其开发渠道包括在实体瘤癌症的其他治疗环境中对 TIL 细胞疗法进行多中心试验。Amtagvi 和 Proleukin 是治疗方案的一部分，该方案还包括淋巴细胞清除。该公司还在开发使用 TIL 的下一代疗法，例如转基因 TIL 细胞疗法。
Iovance Biotherapeutics Inc简介
公司代码IOVA
公司名称Iovance Biotherapeutics Inc
上市日期Jun 20, 2008
CEODr. Frederick G. Vogt, J.D., Ph.D.
员工数量838
证券类型Ordinary Share
年结日Jun 20
公司地址825 Industrial Road
城市SAN CARLOS
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编94070
电话16502607120
网址https://www.iovance.com/
公司代码IOVA
上市日期Jun 20, 2008
CEODr. Frederick G. Vogt, J.D., Ph.D.
Iovance Biotherapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
434.56K
+7.40%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
212.86K
+1.43%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
99.69K
+6.47%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
Mr. Wayne P. Rothbaum
Mr. Wayne P. Rothbaum
Independent Director
Independent Director
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Dr. Friedrich Graf Finckenstein, M.D.
Dr. Friedrich Graf Finckenstein, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
434.56K
+7.40%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
212.86K
+1.43%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
99.69K
+6.47%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
暂无数据
地区USD
名称
营收
占比
United States
58.60M
97.75%
Rest of world
1.35M
2.25%
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
MHR Fund Management LLC
8.01%
Quogue Capital L.L.C.
7.76%
The Vanguard Group, Inc.
6.92%
BlackRock Institutional Trust Company, N.A.
5.39%
Long Focus Capital Management LLC
3.27%
其他
68.67%
持股股东
持股股东
占比
MHR Fund Management LLC
8.01%
Quogue Capital L.L.C.
7.76%
The Vanguard Group, Inc.
6.92%
BlackRock Institutional Trust Company, N.A.
5.39%
Long Focus Capital Management LLC
3.27%
其他
68.67%
股东类型
持股股东
占比
Investment Advisor
21.59%
Hedge Fund
16.62%
Investment Advisor/Hedge Fund
9.57%
Private Equity
8.01%
Venture Capital
7.77%
Research Firm
5.50%
Individual Investor
0.33%
Bank and Trust
0.25%
Pension Fund
0.20%
其他
30.16%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
649
251.80M
69.59%
-52.91M
2025Q2
654
271.34M
81.00%
-28.55M
2025Q1
680
275.16M
84.08%
-27.55M
2024Q4
654
278.66M
85.07%
-21.74M
2024Q3
641
272.75M
89.13%
-24.76M
2024Q2
630
269.09M
94.68%
-12.01M
2024Q1
622
253.92M
89.61%
-22.91M
2023Q4
605
240.15M
93.91%
-35.32M
2023Q3
601
248.03M
97.72%
-14.72M
2023Q2
594
232.36M
107.55%
-14.37M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
MHR Fund Management LLC
28.97M
8.01%
+4.55M
+18.63%
Jun 30, 2025
Quogue Capital L.L.C.
28.07M
7.76%
--
--
Apr 17, 2025
The Vanguard Group, Inc.
25.03M
6.92%
-2.70M
-9.74%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
19.50M
5.39%
-1.03M
-5.02%
Jun 30, 2025
Long Focus Capital Management LLC
11.82M
3.27%
+2.57M
+27.78%
Jun 30, 2025
State Street Investment Management (US)
9.89M
2.73%
-1.15M
-10.42%
Jun 30, 2025
Millennium Management LLC
9.33M
2.58%
+9.17M
+5793.16%
Jun 30, 2025
Invenomic Capital Management LP
8.29M
2.29%
+2.80M
+51.09%
Jun 30, 2025
Two Sigma Investments, LP
7.01M
1.94%
+6.62M
+1666.83%
Jun 30, 2025
Geode Capital Management, L.L.C.
6.19M
1.71%
+220.76K
+3.70%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月2日 周日
更新时间: 11月2日 周日
机构名称
占比
Virtus LifeSci Biotech Products ETF
1.56%
iShares Genomics Immunology and Healthcare ETF
1.33%
WisdomTree BioRevolution Fund
0.64%
Tema Oncology ETF
0.54%
Invesco NASDAQ Future Gen 200 ETF
0.47%
SPDR S&P Biotech ETF
0.27%
Direxion Daily S&P Biotech Bull 3X Shares
0.15%
Invesco Nasdaq Biotechnology ETF
0.08%
ProShares Ultra Nasdaq Biotechnology
0.08%
iShares Biotechnology ETF
0.06%
查看更多
Virtus LifeSci Biotech Products ETF
占比1.56%
iShares Genomics Immunology and Healthcare ETF
占比1.33%
WisdomTree BioRevolution Fund
占比0.64%
Tema Oncology ETF
占比0.54%
Invesco NASDAQ Future Gen 200 ETF
占比0.47%
SPDR S&P Biotech ETF
占比0.27%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.15%
Invesco Nasdaq Biotechnology ETF
占比0.08%
ProShares Ultra Nasdaq Biotechnology
占比0.08%
iShares Biotechnology ETF
占比0.06%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
